Copy

Sebia 
ESL Biosciences, in partnership with Sebia, offer the most comprehensive range of electrophoresis diagnostic technologies

New Publication on Sebia Free Light Chain ELISA and the DAS AP22 ELITE Instrument

Measurement of the serum level of free light chains (FLC) is used as an aid in the diagnosis, prognosis and monitoring of of multiple myeloma and related disorders.  Sebia and the Laboratory of Medical Immunology in Nijmegen co-developed an anti-FLCs ELISA assay based on polyclonal antibodies which can be processed on the DAS AP22 ELITE ELISA platform (DAS, Italy).
Recently Lutteri et al at the University Hospital of Liège in Belgium published a paper that evaluates the performance of the Sebia FLC ELISA on DAS AP22 ELITE processor, and compared the results with Freelite processed on the SPA PLUS analyzer (The Binding Site).
Paper Highlights
  • Sebia FLC ELISA is a reproducible assay, requiring less retesting than Freelite
  • Sebia FLC results are closer (around a 1.3-fold increase) to peak estimation by electrophoresis than Freelite
  • High concordance was found with results obtained with Sebia FLC ELISA and Freelite
    • However, the results from the two assays are not interchangable
  • Sebia FLC ELISA showed a good performance using the DAS AP22 ELITE processor
Link to the Publication
Please contact your area ESL sales representative for a copy of the publication, and more information on Sebia Free Light Chains ELISA tests with DAS AP22 ELITE ELISA processor
NZ
NZ
Website
Website
Twitter
Twitter
Facebook
Facebook
LinkedIn
LinkedIn
Google+
Google+
Copyright © 2018 ESL Biosciences (New Zealand) Limited. All rights reserved.